Status:

COMPLETED

A Phase 2b Study of Icosabutate in Fatty Liver Disease

Lead Sponsor:

NorthSea Therapeutics B.V.

Conditions:

Non Alcoholic Steatohepatitis (NASH)

Eligibility:

All Genders

18-75 years

Phase:

PHASE2

Brief Summary

A Phase 2b study to evaluate the efficacy of different doses of NST-4016 on the resolution of NASH without worsening of fibrosis

Detailed Description

This is a 62 week (including screening and follow-up), multicenter, randomized, double blind, placebo-controlled, parallel group study in male and female patients with a histological diagnosis of NASH...

Eligibility Criteria

Inclusion

  • Provides signed written informed consent and agrees to comply with the study protocol.
  • Is a male or female aged 18 to 75 years, inclusive.
  • Has a histological diagnosis of NASH prior to study entry
  • Has (NAS) greater than or equal to 4, with a score of at least 1 in each component (steatosis, lobular inflammation, and ballooning),
  • Has a fibrosis score F1 to F3, inclusive (F1 capped at 30%),
  • Has a Proton Density Fat Fraction (PDFF) greater than or equal to 10% on MRI at screening

Exclusion

  • Has a known history of alcohol abuse or daily heavy alcohol consumption
  • Has had bariatric surgery within the past 5 years
  • Has significant systemic or major illnesses other than liver disease
  • Has a recent (within 6 months) history of cardiac dysrhythmias and/or cardiovascular disease
  • Has uncontrolled arterial hypertension
  • Positive for Hep B, Hepatitis C Virus (HCV) or HCV Polymerase Chain Reaction (PCR)
  • Has type 1 diabetes mellitus
  • Has diabetic ketoacidosis
  • Has a history of liver decompensation

Key Trial Info

Start Date :

July 17 2019

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 19 2022

Estimated Enrollment :

280 Patients enrolled

Trial Details

Trial ID

NCT04052516

Start Date

July 17 2019

End Date

December 19 2022

Last Update

February 28 2025

Active Locations (39)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 10 (39 locations)

1

Central ResearchAssociates Inc.

Birmingham, Alabama, United States, 35205

2

Arizona Liver Health

Chandler, Arizona, United States, 85224

3

Arizona Liver Health - Glendale

Glendale, Arizona, United States, 85306

4

Arizona Liver Health

Tucson, Arizona, United States, 85711

A Phase 2b Study of Icosabutate in Fatty Liver Disease | DecenTrialz